Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)

An Open-Label, Clinical Pharmacology Study to Investigate Drug-Drug Interaction in Patients With RA

This is an open-label, clinical pharmacology study to investigate drug-drug interaction in patients with RA.

Inclusion criteria

• Patients who are diagnosed with RA according to the 1987 American College of Rheumatology (ACR) classification criteria
• Patients who contracted RA at least 6 months prior

Exclusion criteria

• Patients with Class IV Steinbrocker functional impairment at enrollment.
• Patients who have been treated for the underlying disease with a biological agent, such as infliximab or etanercept and have been receiving treatment with leflunomide, within 12 weeks before initiation of treatment with the probe drug